Browse > Article
http://dx.doi.org/10.3345/kjp.2008.51.12.1336

Distribution of CD4+CD25+ T cells and graft-versus-host disease in human hematopoietic stem cell transplantation  

Lee, Dae Hyoung (Department of Pediatrics, College of Medicine, Hallym University)
Chung, Nak Gyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Jeong, Dae Chul (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Cho, Bin (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Kim, Hack Ki (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Publication Information
Clinical and Experimental Pediatrics / v.51, no.12, 2008 , pp. 1336-1341 More about this Journal
Abstract
Purpose : This study aimed to determine the frequencies of $CD4^+CD25^+$ T cells in donor graft and peripheral blood $CD4^+CD25^+$ T cells in recipients after hematopoietic stem cell transplantation (HSCT) and their association with graft-versus-host disease (GVHD). Methods : Seventeen children who underwent HSCT were investigated. $CD4^+CD25^+$ T cells in samples from donor grafts and recipient peripheral blood were assessed by flow cytometry at 1 and 3 months after transplantation. Results : $CD4^+CD25^+$ T cell frequencies in the grafts showed no significant difference between patients with and without acute GVHD (0.90% vs. 1.06%, P=0.62). Absolute $CD4^+CD25^+$ T cell number in grafts were lower in patients with acute GVHD than in those without acute GVHD ($6.18{\times}10^5/kg$ vs. $25.85{\times}10^5/kg$, P=0.09). Patients without acute GVHD showed a significant decrease in peripheral blood $CD4^+CD25^+$ T cell percentage at 3 months compared to those at 1 month after HSCT (2.11% vs. 1.43%, P=0.028). However, in patients with acute GVHD, $CD4^+CD25^+$ T cell percentage at 3 months was not different from the corresponding percentage at 1 month after HSCT (2.47% vs. 2.30%, P=0.5). Conclusion : The effect of frequencies of $CD4^+CD25^+$ T cells in donor grafts on acute GVHD after HSCT could not be identified, and the majority of peripheral blood $CD4^+CD25^+$ T cells in patients who underwent HSCT may be activated T cells related to acute GVHD rather than regulatory T cells. Further studies with additional markers for regulatory T cells are needed to validate our results.
Keywords
Regulatory T cell; Graft-versus-fost Disease; Allogeneic hematopoietic stem cell transplantation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type $CD4^＋CD25^＋$ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation J Exp Med 2002;196:389-99   DOI
2 Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. $CD4^＋$ CD25high Regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53   DOI
3 Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui WH, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004;104: 2187-93   DOI   ScienceOn
4 Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006;43:3-10   DOI   ScienceOn
5 Teshima T, Ferrara JL. Pathogenesis and prevention of graft-versus-host disease. Curr Opin Organ Transplant 2001; 6:265-71   DOI   ScienceOn
6 Hanash AM, Levy RB. Donor $CD4^＋CD25^＋$ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 2005;105:1828-36   DOI   ScienceOn
7 Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, et al. Recipient-type specific $CD4^＋CD25^＋$ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versusleukemia. J Clin Invest 2003;112:1688-96   DOI
8 Storek J, Witherspoon RP. Immunological reconstitution after hematopoietic stem cell transplantation. In: Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner MK. Clinical bone marrow and blood stem cell transplantation, 3rd ed. Cambridge: Cambridge University Press, 2004:194-226
9 Sanchez J, Casano J, Alvarez MA, Roman-Gomez J, Martin C, Martinez F, Gomez P, et al. Kinetic of regulatory CD25high and activated $CD134^＋$(OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2004;126:697-703   DOI   ScienceOn
10 Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985;66:664-72
11 Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, et al. CD25 expression on donor CD4 or CD8 T cells is associated with an increased risk for graft-versushost disease after HLA-identical stem cell transplantation in humans. Blood 2004;103:1140-6   DOI   ScienceOn
12 Zorn E, Kim HT, Lee SJ, Floyd BH, Lista D, Arumugarajah S, et al. Reduced frequency of FOXP3＋ $CD4^＋CD25^＋$ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005;106:2903-11   DOI   ScienceOn
13 Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immuno. 2003;3:199-210   DOI   ScienceOn
14 Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded $CD4^＋CD25^＋$ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002;99: 3493-9   DOI   ScienceOn
15 Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62
16 Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64
17 Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor $CD4^＋CD25^＋$ T cells to allow an effective graft-versusleukemia response. Biol Blood Marrow Transplant 2003;9: 243-56   DOI   ScienceOn
18 Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304   DOI   ScienceOn
19 Auletta JJ, Lazarus HM. Immune restoration following hematopoietic stem cell transplantation: an evolving target. Bone Marrow Transplant 2005;35:835-57   DOI   ScienceOn
20 Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. $CD4^＋CD25^＋$ immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002;196:401-6   DOI
21 Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by $CD4^＋CD25^＋$ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32   DOI   ScienceOn
22 Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M, et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood $CD4^＋$ CD25 high regulatory T cells. Blood 2004;103:2410-6   DOI   ScienceOn